Literature DB >> 21762615

Malaria, Oromia regional state, Ethiopia, 2001-2006.

Dereje Olana, Sheleme Chibsa, Dawit Teshome, Addis Mekasha, Patricia M Graves, Richard Reithinger.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 21762615      PMCID: PMC3381418          DOI: 10.3201/eid1707.100942

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: In Ethiopia, malaria is unstable and commonly occurs as intraannual and interannual epidemics. Transmission is associated with altitude, temperature, and rainfall, generally peaking twice a year, after the 2 rainy seasons (March–May and July–September) (). Cases are caused by Plasmodium falciparum and P. vivax. Anopheles arabiensis mosquitoes are the main vector for both species. Although malaria is the most common communicable disease in Ethiopia (), few longitudinal case data has been published (). We report a retrospective analysis of outpatient data for July 2001–June 2006 obtained from all secondary and tertiary government-run health facilities (152 health centers and 25 hospitals) in Oromia Regional State. Oromia has 17 administrative zones and 297 districts. Data were reported monthly on paper forms by health facility staff at district level to the Oromia Regional Health Bureau Zonal Health Offices, which aggregated zonal data before forwarding them to the Oromia Regional Health Bureau Malaria Control Department. Data obtained included number of outpatient cases (i.e., patients attending the health facility grouped by age <5 years and age >5 years); number of clinical malaria cases (i.e., patients with fever grouped by age and sex); number of clinical cases confirmed by microscopy; and number of cases caused by P. falciparum and P. vivax. If no outpatient data were reported, the case number was changed from zero to missing. The data were entered into Microsoft Excel (Microsoft, Redmond, WA, USA) and analyzed by using Stata version 9.0 (StataCorp LP, College Station, TX, USA). During 2001–2006, a total of 8,786,088 outpatient consultations were reported. A total of 905,467 and 562,996 clinical and confirmed malaria cases, respectively, were reported. Patients were predominantly seen at health centers rather than at hospitals, with 80.2% clinical and 72.2% confirmed malaria cases seen at health centers. Clinical malaria accounted for 10.3% of outpatient consultations in all facilities. However, this percentage varied between years (6.1%–16.0%) and zones (1.3%–21.9%) (Technical Appendix Figure 1). Of clinical malaria cases, 16.5% were in children <5 years of age (range between years [RBY] 14.0%–18.3%, range between zones [RBZ] 10.9%–61.0%) and 54.3% were in male patients (RBY 52.2%–55.6%, RBZ 50.1%–66.8%). Of clinical malaria cases, 49.2% were confirmed by microscopy (RBY 37.1%–58.0%, RBZ 15.3%–98.4%), and 58.5% (RBY 46.4%–63.4%, RBZ 12.1%–82.4%), and 41.2% (RBY 36.3%–53.4%, RBZ 17.6%–87.9%) of confirmed cases were caused by P. falciparum and P. vivax, respectively. Of confirmed cases, 0.4% were caused by mixed Plasmodium infections (RBY 0.2%–0.5%, RBZ 0.0%–1.1%). The average incidence of clinical malaria per 100,000 population per month ranged from 14 in February 2002 to 122 in November 2003, and there was considerable variation between months, years, and administrative zones (Technical Appendix Figure 2). We found that up to 29.0% of outpatient visits to health facilities in certain administrative zones during high transmission years were for malaria. The incidence of malaria is likely to be underestimated because only ≈30% of the population accessed health facilities at that time (). There appeared to be only 1 annual peak of transmission in September–January (Technical Appendix Figure 1). Clinical and confirmed disease varied between zones; 5 of the 15 zones in Oromia (East Hararge, East Shoa, East Wellega, Jimma, West Hararge) reported >75% of the clinical cases seen at health facilities during 2001–2006. Malaria incidence varied between years: clinical and confirmed cases increased in 2003, the last epidemic year recorded in Oromia (), before decreasing to 2001 levels in 2004 (Technical Appendix Figure 1). The P. falciparum to P. vixax ratio changed geographically and temporally (Technical Appendix Figure 1), and increases in the proportion of P. falciparum cases coincided with the peak malaria transmission season. In the epidemic year of 2003, the proportion of P. falciparum cases was larger than in other years, and children <5 years of age were disproportionately affected (Technical Appendix Figure 1). Contrary to previous reports (), our data did not indicate a change in the P. falciparum to P. vivax ratio after artemether/lumefantrine was introduced in 2005. Health facility data can have many caveats (), including concerns about data representativeness (e.g., if only a small number of facilities are assessed); data validity, particularly if, as was the case during that time, only limited diagnostic quality assurance was available (); and analytical approaches used. Our analysis comprised all Oromia secondary and tertiary facilities; only 3.4% of health centers and 13.0% of hospitals surveyed had no data, suggesting that given the extensive data reported, these missing data would have only marginally affected the temporal and spatial trends observed. Our data complement those of recent cross-sectional surveys () and provide a useful baseline to assess scale-up of malaria prevention and control efforts. Unlike cross-sectional and small-scale facility surveys (), our comprehensive longitudinal monthly data monitored disease trends spatially and temporally, showing that malaria still represented a major health services problem until 2006.

Technical Appendix

Outpatient, clinical, and parasitologically confirmed malaria in Oromia Regional State, Ethiopia, 2001-2006. Figure 1. Number of total clinical malaria cases (bars) and cases in children <5 years of age (thick line), proportion of clinical malaria cases confirmed parasitologically (dashed line), and proportion of confirmed malaria cases caused by Plasmodium falciparum (solid line). Figure 2. Annual incidence of clinical malaria cases/100,000 population in individual administrative zones (gray lines) and average malaria incidence (thick line).
  6 in total

1.  Laboratory malaria diagnostic capacity in health facilities in five administrative zones of Oromia Regional State, Ethiopia.

Authors:  Bereket Hailegiorgis; Samuel Girma; Zenebe Melaku; Takele Teshi; Leykun Demeke; Sintayehu Gebresellasie; Damtew Yadeta; Gudeta Tibesso; Nicole Whitehurst; Emanuel Yamo; Jane Carter; Richard Reithinger
Journal:  Trop Med Int Health       Date:  2010-10-08       Impact factor: 2.622

2.  Magnitude of malaria admissions and deaths at hospitals and health centers in Oromia, Ethiopia.

Authors:  Wakgari Deressa; Dereje Olana; Shelleme Chibsa
Journal:  Ethiop Med J       Date:  2004-10

3.  Rapid increase in ownership and use of long-lasting insecticidal nets and decrease in prevalence of malaria in three regional States of ethiopia (2006-2007).

Authors:  Estifanos Biru Shargie; Jeremiah Ngondi; Patricia M Graves; Asefaw Getachew; Jimee Hwang; Teshome Gebre; Aryc W Mosher; Pietro Ceccato; Tekola Endeshaw; Daddi Jima; Zerihun Tadesse; Eskindir Tenaw; Richard Reithinger; Paul M Emerson; Frank O Richards; Tedros Adhanom Ghebreyesus
Journal:  J Trop Med       Date:  2010-09-23

4.  Malaria epidemics and interventions, Kenya, Burundi, southern Sudan, and Ethiopia, 1999-2004.

Authors:  Francesco Checchi; Jonathan Cox; Suna Balkan; Abiy Tamrat; Gerardo Priotto; Kathryn P Alberti; Jean-Paul Guthmann
Journal:  Emerg Infect Dis       Date:  2006-10       Impact factor: 6.883

5.  Caution is required when using health facility-based data to evaluate the health impact of malaria control efforts in Africa.

Authors:  Alexander K Rowe; S Patrick Kachur; Steven S Yoon; Matthew Lynch; Laurence Slutsker; Richard W Steketee
Journal:  Malar J       Date:  2009-09-03       Impact factor: 2.979

6.  Initial evidence of reduction of malaria cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria prevention and treatment.

Authors:  Mac Otten; Maru Aregawi; Wilson Were; Corine Karema; Ambachew Medin; Worku Bekele; Daddi Jima; Khoti Gausi; Ryuichi Komatsu; Eline Korenromp; Daniel Low-Beer; Mark Grabowsky
Journal:  Malar J       Date:  2009-01-14       Impact factor: 2.979

  6 in total
  9 in total

1.  The effect of household heads training about the use of treated bed nets on the burden of malaria and anaemia in under-five children: a cluster randomized trial in Ethiopia.

Authors:  Amare Deribew; Zewdie Birhanu; Lelisa Sena; Tariku Dejene; Ayalu A Reda; Morankar Sudhakar; Fessehaye Alemseged; Fasil Tessema; Ahmed Zeynudin; Sibhatu Biadgilign; Kebede Deribe
Journal:  Malar J       Date:  2012-01-06       Impact factor: 2.979

2.  Polymorphisms in chloroquine resistance-associated genes in Plasmodium vivax in Ethiopia.

Authors:  Lemu Golassa; Berhanu Erko; Frederick N Baliraine; Abraham Aseffa; Göte Swedberg
Journal:  Malar J       Date:  2015-04-16       Impact factor: 2.979

3.  Population-level estimates of the proportion of Plasmodium vivax blood-stage infections attributable to relapses among febrile patients attending Adama Malaria Diagnostic Centre, East Shoa Zone, Oromia, Ethiopia.

Authors:  Lemu Golassa; Michael T White
Journal:  Malar J       Date:  2017-07-27       Impact factor: 2.979

4.  In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.

Authors:  Jimee Hwang; Bereket Hailegiorgis Alemayehu; Richard Reithinger; Samuel Girma Tekleyohannes; Sintayehu Gebresillasie Birhanu; Leykun Demeke; David Hoos; Zenebe Melaku; Moges Kassa; Daddi Jima; Joseph L Malone; Henry Nettey; Michael Green; Amanda Poe; Sheila Akinyi; Venkatachalam Udhayakumar; S Patrick Kachur; Scott Filler
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

5.  Analysis of malaria surveillance data in Ethiopia: what can be learned from the Integrated Disease Surveillance and Response System?

Authors:  Daddi Jima; Milliyon Wondabeku; Abebe Alemu; Admas Teferra; Nuraini Awel; Wakgari Deressa; Adamu Adissie; Zerihun Tadesse; Teshome Gebre; Aryc W Mosher; Frank O Richards; Patricia M Graves
Journal:  Malar J       Date:  2012-09-17       Impact factor: 2.979

6.  Identification of different malaria patterns due to Plasmodium falciparum and Plasmodium vivax in Ethiopian children: a prospective cohort study.

Authors:  Dinberu Seyoum; Yehenew Getachew Kifle; Virginie Rondeau; Delenasaw Yewhalaw; Luc Duchateau; Angel Rosas-Aguirre; Niko Speybroeck
Journal:  Malar J       Date:  2016-04-14       Impact factor: 2.979

7.  Analysis of asymptomatic and clinical malaria in urban and suburban settings of southwestern Ethiopia in the context of sustaining malaria control and approaching elimination.

Authors:  Guofa Zhou; Delenasaw Yewhalaw; Eugenia Lo; Daibin Zhong; Xiaoming Wang; Teshome Degefa; Endalew Zemene; Ming-chieh Lee; Estifanos Kebede; Kora Tushune; Guiyun Yan
Journal:  Malar J       Date:  2016-04-30       Impact factor: 2.979

8.  Equity in long-lasting insecticidal nets and indoor residual spraying for malaria prevention in a rural South Central Ethiopia.

Authors:  Alemayehu Hailu; Bernt Lindtjørn; Wakgari Deressa; Taye Gari; Eskindir Loha; Bjarne Robberstad
Journal:  Malar J       Date:  2016-07-16       Impact factor: 2.979

9.  Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.

Authors:  Tesfay Abreha; Jimee Hwang; Kamala Thriemer; Yehualashet Tadesse; Samuel Girma; Zenebe Melaku; Ashenafi Assef; Moges Kassa; Mark D Chatfield; Keren Z Landman; Stella M Chenet; Naomi W Lucchi; Venkatachalam Udhayakumar; Zhiyong Zhou; Ya Ping Shi; S Patrick Kachur; Daddi Jima; Amha Kebede; Hiwot Solomon; Addis Mekasha; Bereket Hailegiorgis Alemayehu; Joseph L Malone; Gunewardena Dissanayake; Hiwot Teka; Sarah Auburn; Lorenz von Seidlein; Ric N Price
Journal:  PLoS Med       Date:  2017-05-16       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.